主页 > 生命科学 >
¡¾¼¼Êõ²úÒµ¡¿Ö÷¶¯Í¸Æ¤¸øÒ©¼¼Êõ½¥Ç
Oct 2 2006, 8:00 AM EST
BIOWIRE
Compliance concerns have driven and continue to drive investment in new drug delivery technologies. The transdermal patch and implantable drug reservoirs are two prominent examples of this impact. As work with passive transdermal systems has progressed, so too has the realization of the true extent of the barrier to drug delivery presented by the stratum corneum, the skins outer layer of dead, hydrophobic, keratinized cells. Passive permeation of compounds through the skin became a major problem and very soon restricted the choice of compounds that were eligible for delivery in that manner.
To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. Another approach is the modification or removal of surface skin layers, a group of technologies collectively referred to as microporation, which can be used alone or in conjunction with energy-enabled devices to expand the size and type of drug molecules capable of transdermal delivery. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery.
These findings are examined in a new and comprehensive survey written and researched by Greystone Associates. The survey concludes that to take full advantage of these evolving dynamics, active transdermal delivery participants must deal with a number of economic and market forces influencing the way drug companies develop and commercialize their products. Success will favor those sector participants willing to incorporate patient-centric design features and drug-device combination engineering paradigms into their product development programs.
More information is available at www.greystoneassociates.org.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment. Ö÷¶¯Í¸Æ¤¸øÒ©¼¼Êõ½¥Ç÷³ÉÊì
10.2£¬2006£¬8£º00£¬ÃÀ¹ú¶«²¿Ê±¼ä
Biowire
¶Ô·þҩ˳ӦÐԵĹØ×¢ÒѾ²¢½«¼ÌÐøÍƶ¯ÔÚеĸøÒ©¼¼Êõ·½ÃæµÄͶ×Ê¡£Í¸Æ¤Ìù¼ÁºÍÖ²Èëʽ»ºÊͼÁÊÇÕâÒ»£¨Í¶×Ê£©±³¾°ÏµÄÁ½¸öµäÐÍÀý×Ó¡£Ëæ×ű»¶¯Í¸Æ¤¸øÒ©¼¼ÊõµÄ·¢Õ¹£¬ÈËÃǶÔÓÚÒ©ÎïÊÍ·ÅÆÁÕÏʵ¼Ê·¶Î§µÄÁ˽âÒ²ÈÕÒæ¼ÓÉî¡£ÕâЩҩÎïÊÍ·ÅÆÁÕÏ°üÀ¨½ÇÖʲ㣬Ƥ·ôÍâ²ãµÄËÀƤ£¬ÊèË®²¢ÇÒ½ÇÖÊ»¯Á˵Äϸ°û¡£Ò©Îï͸ƤµÄ±»¶¯ÔËÊä³ÉΪÁË×î´óµÄÎÊÌ⣬²¢½«ÓÉ´ËÏÞÖÆÒԾƤ¸øҩΪºÏÊʸøÒ©·½Ê½µÄÒ©ÎïÑ¡Ôñ·¶Î§¡£
ΪÁËÀ©´ó͸Ƥ¸øÒ©¼¼ÊõµÄÓ¦Ó÷¶Î§£¬Ñз¢ÈËÔ±ÀûÓÃÁ˳¬Éù£¬ÈȺ͵çÁ÷µÈÄÜÔ´ÐÎʽ´Ù½øÖ÷¶¯Í¸Æ¤×ªÔË¡£ÁíÒ»¸ö·½·¨ÊǶÔƤ·ô±í²ã½øÐÐÐÞÊλòÕßÒƳý£¬ÕâһϵÁеĸøÒ©¼¼Êõ¹ã·º²ÉÓÃÁË΢¿××°ÖᣴËÖÖ×°ÖÿÉÒÔµ¥¶ÀʹÓÃÒ²¿ÉÒÔºÍÆäËûÄÜÔ´Çý¶¯×°ÖÃÁªºÏʹÓã¬Ôö¼ÓÁËÊʺÏ×ö³É͸Ƥ¸øҩϵͳµÄÒ©Îï·Ö×Ó´óСºÍÀàÐÍ¡£
ÕâЩ·¢ÏÖÒѾÔÚÒ»ÏîеĹ㷺µ÷²éÖеõ½ÆÀ¹À£¬ÕâÏîµ÷ÑÐÓÉGreystoneлá×éÖ¯²¢·ÖÎöÑо¿¡£µ÷²éµÃ³öµÄ½áÂÛÊÇ£¬ÎªÁ˳ä·ÖÀûÓÃÓÐ×ÅÏȽø¶¯Á¦Ñ§ÌØÐÔµÄÖ÷¶¯Í¸Æ¤¸øÒ©¼¼Êõ£¬Ñз¢Õß±ØÐ뿼ÂÇһϵÁÐÓ°ÏìÖÆÒ©ÆóÒµÑз¢ÏúÊ۵ľ¼ÃºÍÊг¡ÒòËØ¡£ÖÂÁ¦ÓÚ°ÑÒÔ²¡ÈËΪÖÐÐĵÄÉè¼ÆÀíÄîºÍÒ©ÎøÒ©×°ÖÃÍêÃÀ½áºÏµÄ¹¤³Ìѧ²úƷһͬÕûºÏµ½²úÆ·¿ª·¢ÏîÄ¿µÄ¹«Ë¾½«»á³É¹¦¡£
¸ü¶àÐÅÏ¢Çë¿´£º
www.greystoneassociates.org.
¹ØÓÚGreystone
Greystone Associates ÊÇÒ»¼ÒÒ½ÁƺÍÎÀÉú±£½¡¹ËÎʹ«Ë¾£¬ÌṩսÂÔÖƶ¨£¬·çÏÕͶ×Ê£¬²úÆ·ÏúÊÛÒÔ¼°¼¼ÊõºÍÊг¡ÆÀ¹ÀµÈÖî¶à·½ÃæµÄ·þÎñ¡£ [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-12 17:14
医学,生命科学网